Prescription ·Strong evidence ·Reviewed May 2026
Erythromycin is a macrolide antibiotic used to treat a range of bacterial infections, including respiratory tract infections, skin and soft-tissue infections, pertussis, and certain sexually transmitted infections. It is a long-standing alternative for patients with penicillin allergy and is also used topically and ophthalmically. Clinically it is notable as a potent inhibitor of the CYP3A4 enzyme, giving it a high potential for drug-drug interactions.
The bottom line
Evidence rating strong. Most-documented uses: community-acquired respiratory tract infections (pharyngitis, bronchitis, atypical pneumonia), skin and soft-tissue infections, pertussis (whooping cough) treatment and prophylaxis. 3 sources indexed (1992–2004), with 6 interaction records on file.
Core mechanism
Erythromycin binds reversibly to the 50S ribosomal subunit of susceptible bacteria, specifically to the 23S ribosomal RNA in the peptidyl transferase region. This binding blocks the exit tunnel for the growing polypeptide chain and inhibits the translocation step of protein synthesis, halting bacterial growth. The effect is generally bacteriostatic but can be bactericidal at high concentrations against highly susceptible organisms. Erythromycin also acts as a motilin receptor agonist in the gastrointestinal tract, which accounts for both its prokinetic effects and its dose-related nausea and cramping. As a strong inhibitor of cytochrome P450 3A4, it can markedly raise plasma concentrations of many co-administered drugs metabolized by that pathway.1,2
Erythromycin base and stearate are acid-labile and are best absorbed on an empty stomach, typically 30 to 60 minutes before or 2 hours after meals; enteric-coated and delayed-release forms protect the drug from gastric acid. The ethylsuccinate salt may be taken without regard to food. Taking with food can reduce gastrointestinal upset for some patients but may lower absorption of the base and stearate.
Nutrients this medication can lower over time, and what to replace.
Like most broad-spectrum oral antibiotics, erythromycin can suppress vitamin K-producing colonic bacteria. In patients with already marginal vitamin K intake or stores, this may reduce menaquinone (vitamin K2) availability and impair hepatic synthesis of vitamin K-dependent clotting factors. The effect is generally modest and most clinically relevant in patients who are malnourished or concurrently taking warfarin.
Erythromycin can suppress or kill bacterial probiotic organisms if taken at the same time, although selected probiotics may lower antibiotic-associated diarrhea risk.
Recommendation: Separate probiotic doses from the antibiotic by at least 2 hours when feasible; avoid probiotic use in severely immunocompromised patients or patients with central lines unless clinician-directed.
St. John's Wort can induce drug-metabolizing enzymes and transporters and may lower Erythromycin exposure or undermine therapy.
Recommendation: Avoid starting or stopping St. John's Wort without prescriber review while taking Erythromycin.
Prolonged Erythromycin therapy can contribute to reduced vitamin K status in susceptible patients by altering gut flora, with higher concern in poor intake, malabsorption, liver disease, or warfarin use.
Recommendation: Do not self-treat bleeding or INR changes. Monitor for bruising or bleeding and coordinate vitamin K or anticoagulant changes with the prescriber.
St. John's Wort is a potent inducer of CYP3A4 and intestinal P-glycoprotein. Erythromycin is metabolized by CYP3A4 and is a P-gp substrate, so concomitant use can lower erythromycin plasma concentrations and may reduce antibacterial efficacy, risking treatment failure.
Recommendation: Avoid combining St. John's Wort with a course of erythromycin. If an antidepressant or mood supplement is needed, discuss alternatives with the prescriber. Effects of enzyme induction can persist for 1 to 2 weeks after stopping St. John's Wort.
Berberine inhibits CYP3A4 and P-glycoprotein. Erythromycin is itself a CYP3A4 substrate and inhibitor that can prolong the QT interval; adding berberine may raise erythromycin exposure and theoretically compound cardiac risk. Berberine also has its own QT-prolonging potential at higher doses.
Recommendation: Use caution and consider separating or avoiding berberine during a course of erythromycin, particularly in patients with cardiac risk factors, electrolyte abnormalities, or other QT-prolonging medications. Consult a prescriber before combining.
Polyvalent cations such as calcium can bind to some oral antibiotics and reduce absorption. While erythromycin is less prone to cation chelation than tetracyclines or fluoroquinolones, separating high-dose calcium supplements from oral erythromycin is a prudent precaution to ensure consistent absorption.
Recommendation: Separate calcium supplements from oral erythromycin by at least 2 hours where practical. Take erythromycin as directed relative to food per the specific formulation instructions.
Numbered references. Citations throughout the page link here.
Erythromycin acts at the 50S ribosomal subunit to block protein synthesis and inhibits hepatic CYP3A4, raising concentrations of many co-administered substrates.
Current use of oral erythromycin was associated with an increased rate of sudden cardiac death, amplified when combined with CYP3A4 inhibitors.
Exposure to oral erythromycin in the first weeks of life was associated with a substantially increased risk of infantile hypertrophic pyloric stenosis.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
